BioSpace News Archive

PepGen Inc. (Nasdaq: PEPG) today announced that while it awaits receipt of an official clinical hold letter from the U.S. Food and Drug Administration (FDA), the Company is withdrawing its prior guidance with respect to the timeline for initiating a Phase 1 study of PGN-EDODM1 in patients with myotonic dystrophy type 1 (DM1) in the first half of 2023 in any geography.

Zynerba Pharmaceuticals, Inc. announced that it has adjourned its 2023 Annual Meeting of Stockholders solely with respect to Proposal 2 set forth in its Definitive Proxy Statement filed with the Securities and Exchange Commission on April 21, 2023.

RadNet, Inc., a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services, announced that it intends to offer and sell, subject to market and other conditions, an underwritten public offering of $175,000,000 of shares of common stock.

Saskatoon, Saskatchewan--(Newsfile Corp. - June 13, 2023) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the “Company” or “MustGrow”), is pleased to announce the successful initial commercial run-rate production of its mustard plant-based biocontrol liquid via a contract manufacturer.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

Dermata Therapeutics, Inc. announced that Dermata’s CEO, Gerald Proehl, has been invited to present at the Healthcare Virtual Conference Part II, presented by Maxim Group LLC and hosted by M-Vest, on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET.

Baxter International Inc., a global medtech leader, will host a conference call to discuss its second-quarter 2023 financial results on Thursday, July 27, 2023 at 7:30 a.m. Central Time.

Catalent, Inc. announced that the Company has received written notification from the New York Stock Exchange that it has officially regained compliance with the NYSE continued listing standards.

Inventiva (Euronext Paris and Nasdaq: IVA) today announced positive topline results of the clinical study conducted by Dr. Kenneth Cusi from the University of Florida, evaluating lanifibranor in patients with NAFLD and type 2 diabetes mellitus (T2D).

Gencurix, a leading cancer molecular diagnostics company, has obtained approval from the Korean Ministry of Food and Drug Safety for its Droplex EGFR Mutation Test v2.